At the ARVO meeting, Sylentis presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome, and that has enabled the start-up of the phase 3 “Helix” clinical trial.
Sylentis presented the preclinical and clinical results of various compounds that are being developed for the treatment of ocular disorders. Among these, the abstract “Tivanisiran a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials” (Posterboard number: 925 – B0103) is highlighted. The compound improves ocular inflammatory parameters, tear quality, and a reduction in ocular pain associated with dry eye disease, according to Sylentis.
The novel mechanism of action of tivanisiran, based on genetic silencing through RNA interference (RNAi), is targeted at the treatment of the signs and symptoms of this pathology, making it a firm candidate for the treatment of dry eye disease.
“We trust in our technology, innovative in this field, and we hope that tivanisiran will soon become a real alternative for the treatment of millions of people that suffer dry eye disease around the world,” Ana Isabel Jiménez, Director of R&D at Sylentis, said in a news release. “This is a significant step forward in the development of innovative drugs in different therapeutic areas through a novel technology of genetic silencing based on the RNA.”
Sylentis is a pioneer in RNAi research and continues to research new therapies for ophthalmological and inflammatory illnesses.
The phase 3 Helix study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia, and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.
About RNA interference: https://www.youtube.com/watch?v=iXvSitR5184